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Abstract 
Peroxisome proliferator-activated receptor alpha (PPARα) is involved in lipid and 
carbohydrates metabolism. The aim of this study was to test the possible association 
between the PPARA intron 1 A/C polymorphism (rs135539) and the acquirement of 
elite athlete status.. 155 Israeli athletes (male, n=119; female, n=36) and 240 healthy 
controls (male, n=170; female, n=70) participated in the study. The athletes' group 
consisted of endurance athletes (n=74) and sprinters (n=81).  Genotyping was 
performed using PCR-RFLP on DNA from leucocytes. Results showed that genotype 
distribution and allele frequencies were similar (p= 0.65 for genotypes and p=0.48 for 
allele frequency) for the groups of endurance athletes (allele frequency: A/C 0.7/0.3), 
sprinters (allele frequency A/C 0.66/0.34), and controls (allele frequency A/C 
0.71/0.29).,Further, no statistical differences were found between the subgroups of 
elite-level endurance athletes (those who had represented Israel in world track and 
field championships or in the Olympic Games) and national-level endurance athletes 
(p=0.44 for genotypes and p=0.96 for allele frequency), or between elite-level and 
national-level sprinters (p=0.57 for genotypes and p=0.40 for allele frequency). In 
conclusion, the present study found no differences in genotype and allelic frequency 
across PPARA intron 1 A/C polymorphism between endurance athletes, sprinters and 
controls. Further research is needed in other ethnic groups in order to verify these 
results. 
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Introduction 
The search for genes that are involved in the acquirement of elite athlete status is an 
ongoing project, with a growing number of single nucleotide polymorphisms (SNPs) 
being suggested to influence the outcome of elite athletic challenge (Williams & 
Folland, 2008).  
Peroxisome proliferator-activated receptor alpha (PPARα) is a member of the 
steroid hormone receptor superfamily of ligand-activated transcription factors (Yoon, 
2009). PPARα protein is present at high levels in tissues such as liver, skeletal 
muscle, and myocardium, in which catabolism of fatty acids occurs (Braissant et al., 
1996; Liang & Ward, 2006). Upon ligand activation, PPARα binds to PPAR response 
elements (PPREs), which are located in the promoter region of target genes, thereby 
regulating transcription of target genes (Fruchart, 2001) . Among these target genes 
are fatty acid uptake, binding, and activation genes, and mitochondrial β-oxidation 
genes, which are strongly involved in lipid metabolism (Yoon, 2009). Additionally, 
PPARα regulates glucose and energy homeostasis (Guerre-Millo et al., 2000).  
The peroxisome proliferator-activated receptor family also consists of PPARγ and 
PPARδ (Liang & Ward, 2006). All PPARs are subject to transcriptional coactivation 
by peroxisome proliferator-activated receptor gamma coactivator1 (PGC-1α). The 
PPARGC1A Ser482Gly (Eynon et al., 2009a; Eynon et al., 2009b; Lucia et al., 2005) 
and the PPARA intron 7 G/C (Ahmetov et al., 2006) SNPs were shown to be 
associated with elite aerobic performance.  
Previous studies have comprehensively evaluated SNPs within the PPARA gene 
and assessed their association with myocardial infarction (Reinhard et al., 2008) and 
type 2 diabetes (Andrulionyte et al., 2007). The minor C allele of the PPARA A/C 
SNP was found to be associated with MI, and suggested to be a predictor for the 
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development of type 2 diabetes. Interestingly, in both cases this association was 
significant only when it was considered together with other SNPs in the PPARA gene, 
using haplotype analysis.  Since it was recognized that the PPARA gene plays a role in 
glucose and fatty acid metabolism, it might be that this particular polymorphism is 
one of the growing number of polymorphisms that were previously found to be 
associated with elite athletic performance. 
Therefore, the purpose of this study was to analyze the frequency distribution of 
PPARA intron 1 A/C polymorphism (rs135539) in athletic and non-athletic Israeli 
populations, and to compare the frequency distribution of the above polymorphism 
between athletes of sports with different demands (endurance vs. sprinters) as well as 
between competitive levels (elite-level vs. national level).  
 
Material and Methods    
Subjects 
The study followed recent recommendations for replicating genotype-phenotype 
association studies (Chanock et al., 2007). Owing to limitations, genotyping was not 
performed in two independent laboratories using different methodology. One hundred 
and fifty-five track and field athletes (119 men and 36 women, age=35.9+12.2 yrs) 
volunteered to participate in the study. Athletes were included in the study sample 
only if they had participated in national/international track and field championships. 
The control group consisted of 240 non-athletic healthy individuals (167 men and 73 
women) who were randomly selected from the Israeli population. Controls were not 
engaged in physical activity on a regular basis. Athletes were divided into two groups: 
1) An endurance-type group that included 74 long-distance runners (60 men and 14 
women) whose main events were the 10000m run and the marathon; and 2) A sprint-
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type group that included 81 sprinters (59 men and 22 women) whose main events were 
the 100-200m dash and the long jump. According to their individual best 
performances, athletes within each group were further divided into two subgroups: 
elite-level (those who had represented Israel in world track and field championships or 
in the Olympic Games; 28 men and 18 women) and national-level (91 men and 18 
women). All subjects, athletes and non-athletes, were Israeli Caucasians for > 3 
generations, with an equivalent ratio of mixed Jews coming from Arab countries (non-
Ashkenazi) and Jews coming from Europe (Ashkenazi) (2:1, respectively). The study 
was approved by the Helsinki Committee, the formal ethics committee of the Hillel 
Yaffe Medical Center, Hadera, Israel, according to the Declaration of Helsinki. A 
written informed consent was obtained from each participant.  
Genotyping  
Genomic DNA was extracted from peripheral EDTA treated anit-coagulated blood 
using a standard protocol. Genotyping of the PPARA intron 1 A/C (rs135539) was 
performed using polymerase chain reaction (PCR). A 210-bp fragment of the PPARα 
A/C polymorphism was amplified using primers-F 5'- 
CCAGGGGGAGGAAAGAGTGAA -3'
 
and -R 5'- 
GCCACAACTAAGCAGGCAGTG -3'. PCR was performed
 
by denaturation at 94°C 
for 5 min, 34 cycles of denaturation at 94°C for 1 min, annealing
 
at 53°C for 1 min, 
extension at 72°C for 1 min, and
 
a final extension step of 10 min at 72°C. The 
amplified fragment
 
subsequently underwent digestion by Hinf I (New England 
Biolabs,
 
Beverly, MA, USA) in a condition recommended by the supplier. The
 
digested products were then electrophoresed in a 2% agarose
 
gel. This method yields 
148-bp and 62-bp fragments in the presence of the C allele, and 210-bp in the presence 
of the A allele. To ensure proper internal control, for each genotype analysis we used 
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positive and negative controls from different DNA aliquots that were previously 
genotyped with the same method according to recent recommendations for replicating 
genotype-phenotype association studies (Chanock et al., 2007). The RFLP results were 
scored by two experienced and independent investigators who were blind to the 
subject data. 
Data analysis  
The SPSS statistical package, version 17.0, was used to perform all statistical 
evaluations (SPSS Inc., Chicago, IL, USA). Allele frequencies were determined by 
gene counting. A Pearson χ2 test, Yates corrected χ2 test, or Fischer exact test was used 
to confirm that the observed genotype frequencies were in Hardy-Weinberg 
equilibrium, and to compare the PPARA A/C allele and genotype frequencies between 
athletes and control subjects as well as between athletes from different sports and 
different competitive levels. The level of significance was set at P< 0.05. 
Results 
The complete data on allele and genotype frequencies of the PPARA A/C 
polymorphism are shown in Figure 1 and 2. The genotype subtype did not differ by 
gender in the athletes group (χ2 = 0.9, d.f=2, P=0.74) or in the control group (χ2 = 0.4, 
d.f=2, P=0.59). Since the Israeli population includes Caucasians who are mixed non-
Ashkenazi and Ashkenazi, we confirmed that there was an equivalent ratio of non-
Ashkenazi and Ashkenazi descent in each group (2:1), and that there were no 
differences across the PPARA genotype between non-Ashkenazi and Ashkenazi 
descendants (χ2 = 0.09, d.f=2, P=0.71). PPARA genotype distribution was in 
agreement with the Hardy-Weinberg equilibrium within the endurance athletes 
(P=0.13), the sprinters (P=0.16), and the control group (P=0.09). Genotype 
distribution and allele frequencies were similar in the groups of endurance athletes, 
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sprinters, and controls (Figure 2). Further, no statistical differences were found 
between the subgroups of top-level endurance athletes and national-level endurance 
athletes, or between top-level and national-level sprinters (Table 1).  
Discussion 
The results of the present study revealed that the genotype and allele frequency 
distributions of the PPARA A/C polymorphism were similar in the endurance athletes, 
the sprinters, and the control group. Furthermore, genotype and allele frequency 
distributions of the PPARA A/C polymorphism were also similar in the three groups in 
relation to their level of performance (national level vs. elite-level). The PPARA A/C 
polymorphism cannot be used to distinguish endurance athletes from either sprinters 
or sedentary individuals. Previously, genetic examinations of the PPARA locus have 
mainly focused on the intron 7 G/C variant, which has been shown to be associated 
with endurance performance in Russian (Ahmetov et al., 2006) and Israeli (Eynon et 
al., 2009b) elite endurance athletes. In the present study we have determined a possible 
association between PPARA A/C polymorphism and athletes' status in both endurance 
and power-oriented sport disciplines.  
The mechanisms by which a single genetic variant influence the process of 
becoming an elite athlete remain unclear. Many genetic association studies suggest 
that an observed association is mediated through alterations in gene expression. It is 
now believed that an orchestrated signal transduction from contractile activity to the 
gene regulatory machinery occurs during and after exercise training (Yan, Li, & 
Akimoto, 2007). It was reasonable to assume that variation in the PPARA gene will be 
associated with endurance performance since it was found that PPARA mRNA 
expression was significantly higher in type I (oxidative) than type II muscle fibers 
(Ahmetov et al., 2006). It was well established that highly-trained endurance athletes 
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have a relatively high amount of slow-twitch muscle fibers, and sprinters, on the other 
hand, have an excess of fast-twitch fibers (Russell et al., 2003). Thus, part of the 
allelic association with performance phenotypes might be mediated through genotype-
associated alterations in fiber type proportion. 
This study further pursued the essential function of the PPARA gene in fatty acid 
metabolism. PPARα together with PPARδ play an important role in controlling fatty 
acid oxidation (Yoon, 2009). Activation of the PPARα protein results in the increased 
expression of genes involved in lipid oxidation, lipoprotein metabolism, inhibition of 
vascular inflammation, and adipocyte differentiation (Fruchart et al.,1999). Since it is 
well established that endurance-trained athletes derive a greater energy contribution 
via aerobic metabolism, which relies mainly on circulating free fatty acids and 
glucose, and sprint-trained individuals rely more heavily on anaerobic sources such as 
intramuscular stored CP, ATP, and glucose (Nummela & Rusko, 1995), it is possible 
that the traits underlying the endurance phenotype and the sprint phenotypes may 
reflect evolutionary trade-offs between endurance athletes and sprint/power athletes 
(Van Damme et al., 2002). Thus, PPARA gene variations might partly explain not only 
the physiological differences between elite athletes and sedentary controls, but also the 
differences between athletes participating in different sports (e.g, marathon runners vs. 
sprinters).  
We are aware that genetic association studies must be interpreted with caution, 
since there is a non-trivial possibility of a false positive result (Macarthur & North, 
2005). Nevertheless, it should be noted that our study group consisted of highly-
selected Israeli endurance and sprint/power athletes who have a unique phenotype that 
distinguishes them from sedentary subjects.  
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In conclusion, the present study found no difference in either genotype distribution 
or allelic frequency across PPARA intron 1 A/C polymorphism between endurance 
athletes, sprinters and controls. Further research is needed in other cohorts in order to 
verify these results. 
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Tables: 
 
 
Table 1. PPARA intron 1 A/C polymorphism genotype and allele frequencies in 
athletes divided by subgroups.  
 
    Genotype      Allele frequencies 
Athlete groups Competitive             
   level  n AA AC CC Allele A Allele C 
Endurance Elite-level 20 8 (40) 12 (60) 0 (0) 28 (0.70) 12 (0.30) 
 National level 54 25 (46.3) 26 (48.1) 3 (5.6) 76 (0.70) 32 (0.30) 
Sprinters Elite-level 26 9 (34.6) 14 (53.9) 3 (11.5) 32 (0.62) 20 (0.38) 
  National level  55 23 (41.8) 29 (52.7) 3 (5.5) 75 (0.68) 35 (0.32) 
 
Data are presented as absolute and relative values (within parentheses)  
χ2=1.64, d.f.=2, p=0.44  for genotype frequencies between elite and national-level 
endurance athletes 
χ2=0.02, d.f.=1, p=0.96  for allele frequency between elite and national-level 
endurance athletes 
χ2=1.12, d.f.=2, p=0.57  for genotype frequencies between elite and national level 
sprinters 
χ2=0.96, d.f.=1, p=0.40  for allele frequency between elite and national level sprinters 
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Figure legends:  
 
 
Figure 1. PPARA intron 1 A/C polymorphism genotype and allele frequencies in 
athletes and controls. Data is presented as relative values (%).  
 
χ2=1.44, d.f.=2, p=0.49  for genotype frequencies between athletes and controls 
χ2=0.79, d.f.=1, p=0.37  for allele frequency between athletes and controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 14 
 Figure 2. PPARA intron 1 A/C polymorphism genotype and allele frequencies in 
endurance athletes, sprinters, and controls. Data are presented as relative values (%).  
 
χ2=2.43, d.f.=2, p=0.66  for genotype frequencies between endurance athletes, 
sprinters, and controls 
χ2=1.45, d.f.=1, p=0.48  for allele frequency between endurance athletes, sprinters, 
and controls 
 
 
 
 
 
